F-1/A: Hong Kong Pharma Digital Technology Holdings Limited Files for U.S. IPO on Nasdaq

Hong Kong Pharma Digital Technology Holdings Limited, a Cayman Islands holding company, has filed for an initial public offering of its ordinary shares on the Nasdaq Capital Market, aiming to raise capital for business expansion.

Summary

• Hong Kong Pharma Digital Technology Holdings Limited, a Cayman Islands holding company, is planning an initial public offering of 1,000,000 ordinary shares, with an additional 403,685 shares being offered by selling shareholders.
• The company anticipates the initial public offering price to be between $4.00 and $6.00 per share.
• Hong Kong Pharma operates through its subsidiaries in Hong Kong, providing OTC pharmaceutical cross-border e-commerce supply chain services and procurement and distribution.
• The company reported a total revenue of $16,688,364 and a profit of $1,329,717 for the fiscal year ended March 31, 2024.
• The offering is contingent upon the listing of the ordinary shares on the Nasdaq Capital Market under the symbol HKPD.
• The company is considered an emerging growth company and a foreign private issuer, which allows for reduced public company reporting requirements.
• The company expects to be a controlled company under Nasdaq rules, with its CEO holding a majority of the voting power after the offering.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and growth prospects, but also acknowledges significant risks and challenges. The company's leading position in the market and its strategic growth plans contribute to a positive sentiment, while the competitive landscape and regulatory uncertainties temper the overall outlook.

Positives

• The company is a leading provider of third-party supply chain services in Mainland Chinas OTC pharmaceutical cross-border e-commerce market, ranking first in 2022 by revenue.
• The company has a comprehensive suite of supply chain solutions, including pre-consultation, product information review, procuring overseas OTC pharmaceutical products, and logistics.
• The company has advanced proprietary technology infrastructure, including a custom ERP system.
• The company has a seasoned and visionary management team with established market presence.
• The company has experienced significant revenue growth, with a 33% increase from 2023 to 2024.
• The company has a strong customer base, including e-commerce platform logistics partners and merchants on major Chinese e-commerce platforms.

Negatives

• The company faces intense competition in the supply chain services industry.
• The company's business is significantly affected by the development of international commerce and the e-commerce industry.
• The company is subject to risks associated with OTC pharmaceutical inventories and the logistics industry.
• The company relies on dividends from its subsidiaries to fund its cash requirements.
• The company may be subject to a variety of PRC laws and other obligations regarding cyber security, data protection, overseas offerings and/or foreign investment in China-based issuers.
• The company may not be able to maintain a listing of the Ordinary Shares on Nasdaq.
• The company's Chief Executive Officer and Chairman will continue to hold a majority of the voting power after the offering, which will limit or preclude other shareholders ability to influence corporate matters.

Risks

• The company faces intense competition in the supply chain services industry, especially from large logistics providers.
• The company's business is significantly affected by the development of international commerce and the e-commerce industry.
• The company is subject to risks associated with OTC pharmaceutical inventories and the logistics industry.
• The company relies on dividends from its subsidiaries to fund its cash requirements.
• The company may be subject to a variety of PRC laws and other obligations regarding cyber security, data protection, overseas offerings and/or foreign investment in China-based issuers.
• The company may not be able to maintain a listing of the Ordinary Shares on Nasdaq.
• The company's Chief Executive Officer and Chairman will continue to hold a majority of the voting power after the offering, which will limit or preclude other shareholders ability to influence corporate matters.
• The company is exposed to foreign currency risk.
• The company may experience extreme stock price volatility unrelated to its actual or expected operating performance.
• The company may not be able to maintain a listing of the Ordinary Shares on Nasdaq.
• The company may be subject to a variety of PRC laws and other obligations regarding cyber security, data protection, overseas offerings and/or foreign investment in China-based issuers.

Future Outlook

The company intends to leverage its competitive strengths to pursue growth strategies, including upgrading technology, expanding its sales team, and optimizing working capital and operations. The company also intends to keep any future earnings to finance the expansion of its business.

Management Comments

• The company believes its advanced technological capabilities, vast experience in the OTC pharmaceutical supply chain service industry, and e-commerce insights can further entrench its position as an ever more important player in Mainland Chinas OTC pharmaceutical cross-border e-commerce market.
• The company seeks to differentiate itself from competitors with its efficient process, reduced logistics cost, and existing relationships with key players in the industry.
• The company believes it will continue to efficiently scale and generate strong returns with its exceptional services, expanding customer base, and data-driven approach.

Industry Context

The company operates in the growing OTC pharmaceutical cross-border e-commerce market in Mainland China, which is characterized by increasing demand for overseas products and the adoption of online platforms. The company's strategic positioning as a leading provider in this sector places it at the forefront of a promising market opportunity.

Comparison to Industry Standards

• The company ranked first in the OTC pharmaceutical cross-border e-commerce supply chain service market in Mainland China by revenue in 2022, according to the F&S Report.
• The company's revenue growth of 33% from 2023 to 2024 indicates a strong performance compared to the industry average.
• The company's focus on technology and data-driven approaches aligns with industry trends towards digitalization and efficiency.
• The company's comprehensive suite of services, from procurement to delivery, positions it as a one-stop solution provider, which is a competitive advantage in the market.
• The company's established relationships with major e-commerce platforms and logistics partners, such as CaiNiao, are a key differentiator compared to smaller competitors.

Related Party Transactions

• The company has engaged in transactions with its directors, officers and principal shareholders.
• The company has obtained short-term and long-term loans from financial institutions.

Stakeholder Impact

• Shareholders will have the opportunity to invest in a growing company in the OTC pharmaceutical cross-border e-commerce market.
• Employees will benefit from the company's growth and expansion.
• Customers will have access to a wider range of OTC pharmaceutical products through the company's services.
• Suppliers will have the opportunity to partner with a leading player in the industry.
• Creditors will be repaid through the company's cash flows and financing activities.

Next Steps

• The company intends to use the net proceeds of the offering for development and upgrade of its supply chain ERP systems, procurement of warehouse equipment, expansion of its sales and marketing team, and general working capital.
• The company will continue to monitor the situation in Ukraine, the Gaza Strip and globally and assessing its potential impact on its business.
• The company will continue to implement its remediation plan to address material weaknesses in its internal control over financial reporting.

Key Dates

Keywords

OTC pharmaceuticals, cross-border e-commerce, supply chain services, logistics, Hong Kong, Nasdaq, IPO, China, procurement, distribution